{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:53:03Z","timestamp":1791175983553,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2011,5,26]],"date-time":"2011-05-26T00:00:00Z","timestamp":1306368000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1007\/s10549-011-1591-2","type":"journal-article","created":{"date-parts":[[2011,5,25]],"date-time":"2011-05-25T10:58:00Z","timestamp":1306321080000},"page":"429-437","source":"Crossref","is-referenced-by-count":55,"title":["Increased risk for distant metastasis in patients with familial early-stage breast cancer and high EZH2 expression"],"prefix":"10.1007","volume":"132","author":[{"given":"Sharon Hensley","family":"Alford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Toy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia D.","family":"Merajver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celina G.","family":"Kleer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,5,26]]},"reference":[{"key":"1591_CR1","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/bjs.1800730804","volume":"73","author":"D Sarrazin","year":"1986","unstructured":"Sarrazin D, Dewar JA, Arriagada R et al (1986) Conservative management of breast cancer. Br J Surg 73:604\u2013606","journal-title":"Br J Surg"},{"issue":"Suppl 1","key":"1591_CR2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10549-008-0234-8","volume":"112","author":"A Llombart-Cussac","year":"2008","unstructured":"Llombart-Cussac A (2008) Improving decision-making in early breast cancer: who to treat and how? Breast Cancer Res Treat 112(Suppl 1):15\u201324","journal-title":"Breast Cancer Res Treat"},{"key":"1591_CR3","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1093\/emboj\/16.11.3219","volume":"16","author":"G Laible","year":"1997","unstructured":"Laible G, Wolf A, Dorn R et al (1997) Mammalian homologues of the Polycomb-group gene Enhancer of zeste mediate gene silencing in Drosophila heterochromatin and at S. cerevisiae telomeres. EMBO J 16:3219\u20133232","journal-title":"EMBO J"},{"key":"1591_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0167-4781(99)00130-X","volume":"1447","author":"DP Satijn","year":"1999","unstructured":"Satijn DP, Otte AP (1999) Polycomb group protein complexes: do different complexes regulate distinct target genes? Biochim Biophys Acta 1447:1\u201316","journal-title":"Biochim Biophys Acta"},{"key":"1591_CR5","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1146\/annurev.genet.38.072902.091907","volume":"38","author":"L Ringrose","year":"2004","unstructured":"Ringrose L, Paro R (2004) Epigenetic regulation of cellular memory by the Polycomb and Trithorax group proteins. Annu Rev Genet 38:413\u2013443","journal-title":"Annu Rev Genet"},{"key":"1591_CR6","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/0092-8674(91)90383-A","volume":"65","author":"Y Haupt","year":"1991","unstructured":"Haupt Y, Alexander WS, Barri G, Klinken SP, Adams JM (1991) Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in E mu-myc transgenic mice. Cell 65:753\u2013763","journal-title":"Cell"},{"key":"1591_CR7","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.molmed.2004.08.005","volume":"10","author":"JL Hess","year":"2004","unstructured":"Hess JL (2004) MLL: a histone methyltransferase disrupted in leukemia. Trends Mol Med 10:500\u2013507","journal-title":"Trends Mol Med"},{"key":"1591_CR8","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nature04733","volume":"441","author":"LA Boyer","year":"2006","unstructured":"Boyer LA, Plath K, Zeitlinger J et al (2006) Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature 441:349\u2013353","journal-title":"Nature"},{"key":"1591_CR9","doi-asserted-by":"crossref","first-page":"6070","DOI":"10.1128\/MCB.22.17.6070-6078.2002","volume":"22","author":"SS Levine","year":"2002","unstructured":"Levine SS, Weiss A, Erdjument-Bromage H, Shao Z, Tempst P, Kingston RE (2002) The core of the polycomb repressive complex is compositionally and functionally conserved in flies and humans. Mol Cell Biol 22:6070\u20136078","journal-title":"Mol Cell Biol"},{"key":"1591_CR10","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/onc.2008.433","volume":"28","author":"ME Gonzalez","year":"2009","unstructured":"Gonzalez ME, Li X, Toy K et al (2009) Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1. Oncogene 28:843\u2013853","journal-title":"Oncogene"},{"key":"1591_CR11","doi-asserted-by":"crossref","first-page":"11606","DOI":"10.1073\/pnas.1933744100","volume":"100","author":"CG Kleer","year":"2003","unstructured":"Kleer CG, Cao Q, Varambally S et al (2003) EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 100:11606\u201311611","journal-title":"Proc Natl Acad Sci USA"},{"key":"1591_CR12","doi-asserted-by":"crossref","first-page":"7274","DOI":"10.1038\/onc.2008.333","volume":"27","author":"Q Cao","year":"2008","unstructured":"Cao Q, Yu J, Dhanasekaran SM et al (2008) Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 27:7274\u20137284","journal-title":"Oncogene"},{"key":"1591_CR13","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1593\/neo.05472","volume":"7","author":"M Zeidler","year":"2005","unstructured":"Zeidler M, Varambally S, Cao Q et al (2005) The Polycomb group protein EZH2 impairs DNA repair in breast epithelial cells. Neoplasia 7:1011\u20131019","journal-title":"Neoplasia"},{"key":"1591_CR14","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ccr.2010.10.035","volume":"19","author":"CJ Chang","year":"2011","unstructured":"Chang CJ, Yang JY, Xia W et al (2011) EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-beta-catenin signaling. Cancer Cell 19:86\u2013100","journal-title":"Cancer Cell"},{"key":"1591_CR15","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1158\/0008-5472.CAN-10-1933","volume":"71","author":"ME Gonzalez","year":"2011","unstructured":"Gonzalez ME, DuPrie ML, Krueger H, Merajver SD, Ventura AC, Toy KA, Kleer CG (2011) Histone methyltransferase EZH2 induces Akt-dependent genomic instability and BRCA1 inhibition in breast cancer. Cancer Res 71:2360\u20132370","journal-title":"Cancer Res"},{"key":"1591_CR16","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1093\/emboj\/cdg542","volume":"22","author":"AP Bracken","year":"2003","unstructured":"Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K (2003) EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 22:5323\u20135335","journal-title":"EMBO J"},{"key":"1591_CR17","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.2005.01.5180","volume":"24","author":"IM Bachmann","year":"2006","unstructured":"Bachmann IM, Halvorsen OJ, Collett K et al (2006) EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 24:268\u2013273","journal-title":"J Clin Oncol"},{"key":"1591_CR18","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1158\/1078-0432.CCR-05-1533","volume":"12","author":"K Collett","year":"2006","unstructured":"Collett K, Eide GE, Arnes J et al (2006) Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin Cancer Res 12:1168\u20131174","journal-title":"Clin Cancer Res"},{"key":"1591_CR19","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S1476-5586(03)80032-5","volume":"5","author":"FM Raaphorst","year":"2003","unstructured":"Raaphorst FM, Meijer CJ, Fieret E et al (2003) Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene. Neoplasia 5:481\u2013488","journal-title":"Neoplasia"},{"key":"1591_CR20","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nature01075","volume":"419","author":"S Varambally","year":"2002","unstructured":"Varambally S, Dhanasekaran SM, Zhou M et al (2002) The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419:624\u2013629","journal-title":"Nature"},{"issue":"Suppl 2","key":"1591_CR21","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1038\/modpathol.2008.34","volume":"21","author":"AM Gown","year":"2008","unstructured":"Gown AM (2008) Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol 21(Suppl 2):S8\u2013S15","journal-title":"Mod Pathol"},{"key":"1591_CR22","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10549-006-9242-8","volume":"100","author":"LM McShane","year":"2006","unstructured":"McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100:229\u2013235","journal-title":"Breast Cancer Res Treat"},{"key":"1591_CR23","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1158\/0008-5472.CAN-05-4300","volume":"66","author":"L Ding","year":"2006","unstructured":"Ding L, Erdmann C, Chinnaiyan AM, Merajver SD, Kleer CG (2006) Identification of EZH2 as a molecular marker for a precancerous state in morphologically normal breast tissues. Cancer Res 66:4095\u20134099","journal-title":"Cancer Res"},{"key":"1591_CR24","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/bcr2354","volume":"11","author":"J Puppe","year":"2009","unstructured":"Puppe J, Drost R, Liu X et al (2009) BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A. Breast Cancer 11:R63","journal-title":"Breast Cancer"},{"key":"1591_CR25","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1200\/JCO.1998.16.6.2045","volume":"16","author":"E Chabner","year":"1998","unstructured":"Chabner E, Nixon A, Gelman R et al (1998) Family history and treatment outcome in young women after breast-conserving surgery and radiation therapy for early-stage breast cancer. J Clin Oncol 16:2045\u20132051","journal-title":"J Clin Oncol"},{"key":"1591_CR26","doi-asserted-by":"crossref","first-page":"9352","DOI":"10.1158\/0008-5472.CAN-06-2384","volume":"66","author":"L Ding","year":"2006","unstructured":"Ding L, Kleer CG (2006) Enhancer of Zeste 2 as a marker of preneoplastic progression in the breast. Cancer Res 66:9352\u20139355","journal-title":"Cancer Res"},{"key":"1591_CR27","doi-asserted-by":"crossref","first-page":"R109","DOI":"10.1186\/bcr2135","volume":"10","author":"AM Pietersen","year":"2008","unstructured":"Pietersen AM, Horlings HM, Hauptmann M et al (2008) EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer. Breast Cancer 10:R109","journal-title":"Breast Cancer"},{"key":"1591_CR28","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1159\/000087804","volume":"75","author":"S Arisan","year":"2005","unstructured":"Arisan S, Buyuktuncer ED, Palavan-Unsal N, Caskurlu T, Cakir OO, Ergenekon E (2005) Increased expression of EZH2, a polycomb group protein, in bladder carcinoma. Urol Int 75:252\u2013257","journal-title":"Urol Int"},{"key":"1591_CR29","doi-asserted-by":"crossref","first-page":"8570","DOI":"10.1158\/1078-0432.CCR-05-1047","volume":"11","author":"JD Raman","year":"2005","unstructured":"Raman JD, Mongan NP, Tickoo SK, Boorjian SA, Scherr DS, Gudas LJ (2005) Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder. Clin Cancer Res 11:8570\u20138576","journal-title":"Clin Cancer Res"},{"key":"1591_CR30","first-page":"349","volume":"16","author":"S Weikert","year":"2005","unstructured":"Weikert S, Christoph F, Kollermann J et al (2005) Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas. Int J Mol Med 16:349\u2013353","journal-title":"Int J Mol Med"},{"key":"1591_CR31","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1349-7006.2006.00203.x","volume":"97","author":"Y Matsukawa","year":"2006","unstructured":"Matsukawa Y, Semba S, Kato H, Ito A, Yanagihara K, Yokozaki H (2006) Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci 97:484\u2013491","journal-title":"Cancer Sci"},{"key":"1591_CR32","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1593\/neo.04160","volume":"6","author":"RH Breuer","year":"2004","unstructured":"Breuer RH, Snijders PJ, Smit EF et al (2004) Increased expression of the EZH2 polycomb group gene in BMI-1-positive neoplastic cells during bronchial carcinogenesis. Neoplasia 6:736\u2013743","journal-title":"Neoplasia"},{"key":"1591_CR33","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1038\/sj.bjc.6602531","volume":"92","author":"T Sudo","year":"2005","unstructured":"Sudo T, Utsunomiya T, Mimori K et al (2005) Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma. Br J Cancer 92:1754\u20131758","journal-title":"Br J Cancer"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-011-1591-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-011-1591-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-011-1591-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T16:33:48Z","timestamp":1559234028000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-011-1591-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,26]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["1591"],"URL":"https:\/\/doi.org\/10.1007\/s10549-011-1591-2","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,26]]}}}